FDA Testimony | October 2, 2018
On Tuesday October 2, Daniel Burke, Senior Operations Manager, Cybercrime Investigations Unit of the U.S. Food & Drug Administration testified before the Caucus on the International Narcotics Control. During that testimony, he discussed in detail the importance of WHOIS data/domain name registration information in carrying out their investigations and addressing the opioid issue as well as the difficulty the agency is experiencing given the EU’s GDPR:
“Conducting online investigations is not easy, and FDA has a narrow, but important role in combating the online sale of opioids. For good or bad, much of the Internet ecosystem, including dark nets, have adapted and changed to build in anonymity. Public information about the owner of a domain name, known as ‘whois’ data, is now often impossible to access with the implementation of the European General Data Protection Regulation (GDPR)…”
– Daniel Burke, Senior Operations Manager, Cybercrime Investigations Unit of the U.S. Food & Drug Administration
Read the full testimony here.